Q3 Earnings Estimate for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Investment analysts at HC Wainwright upped their Q3 2025 earnings per share estimates for shares of OPKO Health in a research report issued to clients and investors on Monday, April 7th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings of ($0.07) per share for the quarter, up from their prior forecast of ($0.08). HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s FY2025 earnings at ($0.29) EPS.

A number of other research firms have also issued reports on OPK. Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Price Performance

Shares of OPK opened at $1.42 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm has a market cap of $950.24 million, a PE ratio of -7.45 and a beta of 1.78. OPKO Health has a twelve month low of $1.15 and a twelve month high of $2.04. The firm’s 50 day moving average price is $1.69 and its 200 day moving average price is $1.58.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.

Insider Activity

In other news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The shares were acquired at an average cost of $1.36 per share, for a total transaction of $170,000.00. Following the transaction, the chief executive officer now directly owns 214,001,448 shares of the company’s stock, valued at approximately $291,041,969.28. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. In the last ninety days, insiders bought 1,464,971 shares of company stock valued at $2,268,692. Company insiders own 49.69% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Several institutional investors have recently modified their holdings of the business. Barclays PLC raised its position in OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after buying an additional 329,870 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 217,450 shares in the last quarter. FMR LLC raised its holdings in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in shares of OPKO Health in the fourth quarter worth $102,000. Finally, Essential Planning LLC. acquired a new position in OPKO Health during the fourth quarter worth $506,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.